A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.

Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K

Open source

DOI: 10.1016/j.jtocrr.2021.100262
Published: 2022 Jan
Container: JTO clinical and research reports
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtocrr.2021.100262,
  title = {A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.},
  author = {Camidge DR and Barlesi F and Goldman JW and Morgensztern D and Heist R and Vokes E and Angevin E and Hong DS and Rybkin II and Barve M and Bauer TM and Delmonte A and Dunbar M and Motwani M and Parikh A and Noon E and Wu J and Blot V and Kelly K},
  year = {2022},
  journal = {JTO clinical and research reports},
  doi = {10.1016/j.jtocrr.2021.100262},
  url = {https://doi.org/10.1016/j.jtocrr.2021.100262}
}

RIS

TY  - JOUR
TI  - A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
AU  - Camidge DR
AU  - Barlesi F
AU  - Goldman JW
AU  - Morgensztern D
AU  - Heist R
AU  - Vokes E
AU  - Angevin E
AU  - Hong DS
AU  - Rybkin II
AU  - Barve M
AU  - Bauer TM
AU  - Delmonte A
AU  - Dunbar M
AU  - Motwani M
AU  - Parikh A
AU  - Noon E
AU  - Wu J
AU  - Blot V
AU  - Kelly K
PY  - 2022
JO  - JTO clinical and research reports
DO  - 10.1016/j.jtocrr.2021.100262
UR  - https://doi.org/10.1016/j.jtocrr.2021.100262
ER  -

APA

DR, C., F, B., JW, G., D, M., R, H., E, V., E, A., DS, H., II, R., M, B., TM, B., A, D., M, D., M, M., A, P., E, N., J, W., V, B., & K, K. (2022). A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2021.100262

Source records

pubmed · retrieved 2026-09-26T02:21:41.125Z
europe-pmc · retrieved 2026-09-26T02:21:41.141Z
doaj · retrieved 2026-09-26T02:21:41.175Z